Listen: How the FDA thinks about Covid-19 vaccines, biotech’s SPAC fascination, & Biogen’s case in Alzheimer’s
Check out the latest from The Readout Loud podcast:
“Whose voice rings loudest at the FDA? Is it wise to give hedge funds a blank check? And how will the Biogen saga end?
We discuss all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, STAT’s Helen Branswell joins us to discuss a momentous FDA meeting about Covid-19 vaccines and why its lack of fireworks is heartening to public health experts. Then, University of Michigan business professor Erik Gordon calls in to discuss biotech’s sudden fascination with blank-check companies and the inherent risk that brings. Finally, we dive into aducanumab, Biogen’s oft-debated treatment for Alzheimer’s disease, ahead of an all-important vote in November.”
Click the button below to listen to the podcast:
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?